What's new? Log in Free sign up

Medicus Pharma Ltd. Warrant (MDCX)

Company Profile

Company profile

Ticker

MDCX, MDCXW

Exchange

Incorporated

Ontario, Canada

Location

Ontario, Canada

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

SCCI National Holdings, Inc.

SEC CIK

MDCX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Offering $12.22 mm in Equity

Appointment of agent for service of process by issuers registering securities

Offering $22.67 mm in Equity

Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market

Prospectus supplement

Notice of Change of Auditor

Medicus Pharma LTD. Announces Minor Use (Mums) Designation from the Fda for Doxorubicin-containing Microneedle Array(d-mna) Patch

Medicus Pharma LTD. Announces Collaboration Agreement to Expand Phase 2 Clinical Study In Asia Pacific Region

Prospectus supplement

Current report (foreign)

Latest ownership filings

View all

Melani Kenneth R.

Hathaway John Jason

Frank W Lavelle

Robert J. Ciaruffoli

Institutional ownership, Q3 2024

MDCX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	0.00
Total shares	0.00	0.00
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Medicus Pharma Reports Interim Results in Phase 2 Trial for Non-Invasive Skin Cancer Treatment, Seeks FDA Meeting After Promising 60% Clearance Rate in Basal Cell Carcinoma Study

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin

Medicus Pharma Submits Clinical Design (SKNJCT-004) To UAE DOH To Non-Invasively Treat BCC Of The Skin

The study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital

Medicus Pharma Secures $15M Equity Purchase Agreement With Yorkville Advisors

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") today announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD (the "Investor"), an investment fund managed by

Maxim Group Initiates Coverage On Medicus Pharma with Buy Rating, Announces Price Target of $10

Medicus Pharma Says INAD File No.013880 Received Minor Use In Major Species Designation From FDA For Its Dissolvable D-MNA To Treat External Squamous Cell Carcinoma In Horses

Press releases

From Benzinga Pro

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

PHILADELPHIA, March 06, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

PHILADELPHIA, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is pleased to announce that it has submitted a clinical design (SKNJCT-004) to UAE DOH to

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is currently

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.